Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer

Yonsei Medical Journal

Volumn 46, Issue 4, 2005, Pages 519-525

  Jeong, Joon ^a   Park, Young Nyun ^a   Park, Joon Seong ^a   Yoon, Dong Sup ^a   Chi, Hoon Sang ^a   Kim, Byong Ro ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Immunohistochemisty; p16 genes; p53 genes; Pancreatic cancer

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P16; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHI SQUARE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MOLECULAR GENETICS; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 24644494649     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2005.46.4.519     Document Type: Article

References (28)

1. Ministry of Health and Welfare, Republic of Korea. Annual Report of the Central Cancer Registry in Korea (1997.1.1-1997.12.31);1999.
2. Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg 1999;36:59-152.
3. Crist DW, Cameron JL. The current status of the Whipple operation for periampullary carcinoma. Adv Surg 1992;25:21-49.
4. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995;130:295-300.
5. Yoon DS, Jeong J, Park YN, Kim KS, Kwon SW, Chi HS, et al. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999;40:472-7.
6. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
7. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1996;54:3025-33.
8. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
9. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
10. Huang L, Goodrow TL, Zhang S, Klein-Szanto AJP, Chang H, Ruggeri BA. Deletion and mutation analyses of the p16/MTS1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56: 1137-41.
11. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-7.
12. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF-1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89:469-74.
13. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3.
14. Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, et al. Inactivation of the p6 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998;58:4740-4.
15. Bartsch D, Shevlin DW, Callery MP, Norton JP, Wells Jr SA, Goodfellow PJ. Reduced survival inpatients with ductal pancreatic adenocarcinomas associated with CDKN2 mutation. J Natl Cancer Inst 1996;88:680-2.
16. Eskelinen MJ, Haglund UH. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg 1999;165:292-306.
17. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000;26:29-52.
18. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreat 1997;21:127-43.
19. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions. Cancer 1997;79:700-16.
20. Gansauge F, Gansauge S, Schmidt E, Muller J, Beger HG. Prognostic significance of molecular alterations in human pancreatic carcinoma-an immunohistological study. Langenbecks Arch Surg 1998;383:152-5.
21. Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, et al. Expression of Bcl-2 and p53 protein inresectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol 2001;76:188-96.
22. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-81.
23. Campani D, Boggi U, Cecchetti D, Esposito I, Ceccarelli F, D'Antonio L, et al. p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas 1999;19:26-32.
24. Lynch HT, Brand RE, Lynch JF, Fusaro RM, Kern SE. Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:12-31.
25. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994;118:150-4.
26. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Murray K. P53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994;14:2477-83.
27. Pancreas Club Meeting. May 19, 1996, San Francisco, California. Am J Surg 1997;173:153-8.
28. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996;110:1215-24.